EU MDR & IVDR 2026 Updates for Manufacturers

The European medical device regulatory landscape is changing fast.

For manufacturers working under EU MDR and EU IVDR, compliance in 2026 is no longer just about holding a CE certificate. The focus is shifting toward connected lifecycle compliance, where classification, clinical evidence, performance evaluation, EUDAMED, UDI, PMS, PMCF, PMPF, vigilance, and risk management all work together.

In simple terms, regulators and Notified Bodies now want one clear answer:

Can every important regulatory decision in your technical file be scientifically defended?

EUDAMED Is Becoming a Bigger Compliance Priority

EUDAMED is not just a database. It is becoming a key part of European medical device oversight.

Manufacturers now need to ensure that regulatory data is accurate, controlled, and consistent across documents. Actor details, UDI information, Basic UDI-DI, device classification, certificates, product variants, and device status must all match.

One common issue is inconsistency. The technical file may say one thing, the Declaration of Conformity may say another, and EUDAMED registration may contain a third version.

This can create avoidable regulatory problems.

Manufacturers should treat regulatory master data as controlled technical documentation, not just administrative information.

Classification Needs Fresh Review

Classification remains one of the most important regulatory decisions under MDR and IVDR.

It affects the conformity assessment route, Notified Body involvement, clinical evidence expectations, post-market obligations, and technical documentation requirements.

In 2026, updated MDR and IVDR classification guidance makes one thing very clear: classification should not be based only on the product name.

The intended purpose is central.

Two similar-looking devices may fall into different classes if they differ in duration of use, invasiveness, software function, active characteristics, anatomical location, implantability, or consequences of an incorrect result.

For IVDs, intended purpose is equally critical. Claims made in labels, IFU, websites, brochures, performance evaluation, and sales materials must all tell the same regulatory story.

If marketing claims are broader than regulatory documentation, classification risk increases.

Notified Body Expectations Are Becoming Stricter

Notified Bodies are increasingly looking beyond individual documents.

They expect technical documentation to be structured, traceable, current, scientifically justified, and internally consistent.

This means clinical documentation cannot be treated as a separate folder.

Risk management, clinical evaluation, PMS, PMCF, labelling, and claims must connect clearly. If one section is weak, it can expose gaps in other areas.

For example, if the risk file identifies clinical risks but the CER does not evaluate them, the submission becomes difficult to defend.

Clinical Evaluation Is a Lifecycle Activity

Under MDR, clinical evaluation should not end after CE certification.

A strong clinical evaluation programme should continuously consider safety, performance, clinical benefits, residual risks, state of the art, post-market findings, new literature, complaint trends, vigilance data, and PMCF results.

The CER should not be treated as a document updated once every few years.

A better approach is to treat it as a controlled clinical evidence assessment that is continuously informed by lifecycle data.

This shift is important because post-market evidence can directly affect benefit-risk conclusions.

Clinical Claims Must Be Traceable to Evidence

A claim without evidence is a regulatory liability.

Clinical claims may appear in the IFU, CER, website, brochures, training materials, or distributor materials. If these claims are not supported by appropriate evidence, Notified Bodies may raise questions.

Manufacturers should build a controlled claims matrix.

Each claim should be mapped to the evidence requirement, available evidence, evidence source, and remaining gap.

This helps regulatory teams quickly see which claims are supported and which claims need more evidence.

Clinical Investigation Strategy Should Start With Evidence Gaps

Many manufacturers begin clinical study planning by asking, “How many patients do we need?”

That is not always the best first question.

The better sequence is:

First define the intended purpose. Then identify clinical claims. After that, review existing evidence and define the evidence gap. Only then should the regulatory question, study objective, endpoint, and sample size be planned.

This prevents companies from running studies that generate data but do not close the real regulatory gap.

For example, if the remaining concern is long-term durability, another short-term study may not be useful. The right approach may be longer follow-up, registry data, retrospective follow-up, PMCF, or a targeted prospective study.

IVDR Performance Evaluation Requires a Strong Evidence Strategy

Under IVDR, performance evaluation is more than a performance study.

IVD manufacturers must bring together scientific validity, analytical performance, and clinical performance.

Scientific validity shows the link between the analyte and the clinical condition. Analytical performance shows whether the device can correctly detect or measure the analyte. Clinical performance shows whether the test result is meaningful in the intended population and clinical context.

All three areas should come together in the Performance Evaluation Report.

A weak PER can lead to Notified Body questions, delays, and compliance gaps.

PMPF Is Essential for IVD Lifecycle Evidence

Post-Market Performance Follow-up is not just an IVDR formality.

PMPF helps confirm whether clinical performance remains acceptable after market placement. It can also identify new limitations, population-specific issues, user-related problems, changing disease patterns, or real-world performance concerns.

Methods may include post-market performance studies, literature surveillance, external quality assessment, user feedback, real-world data, registry information, or targeted follow-up activities.

For IVD manufacturers, PMPF should be treated as an ongoing evidence strategy.

PMS and Vigilance Must Feed Back Into the System

PMS data should not sit inside the quality system without action.

Important findings from PMS and vigilance should feed back into risk management, clinical evaluation or performance evaluation, PMCF or PMPF, corrective action, and updated benefit-risk conclusions.

This feedback loop is central to lifecycle compliance.

If complaints, trends, or vigilance findings do not update the CER, PER, RMF, or PMS outputs, the system may appear disconnected.

UDI Is More Than a Labelling Activity

UDI should not be treated as a label-only project.

UDI connects product master data, EUDAMED, labels, certificates, PMS, vigilance, recalls, distribution, and device identification.

Incorrect UDI governance can create downstream regulatory issues.

Manufacturers should ensure UDI information is controlled, aligned, and updated across the technical documentation and regulatory systems.

What Manufacturers Should Prioritise in 2026–2027

Manufacturers should begin with classification and intended purpose.

If classification is wrong, the entire regulatory pathway can be affected. If intended purpose is inconsistent, clinical claims, evidence strategy, and conformity assessment may also become unstable.

Next, manufacturers should map claims to evidence. Any unsupported claim should be reviewed, narrowed, justified, or supported with additional evidence.

Post-market data should also be integrated into risk management, CER, PER, PMCF, PMPF, and benefit-risk evaluation.

Finally, EUDAMED and UDI data should be reviewed before registration or submission to avoid master-data inconsistencies.

The EU MDR and IVDR landscape in 2026 shows one clear message:

Compliance is becoming more connected.

Manufacturers cannot manage CER, PER, RMF, PMS, PMCF, PMPF, IFU, claims, UDI, and EUDAMED as separate activities. Every document should connect to the same evidence model.

The strongest manufacturers will be those who identify evidence gaps before the Notified Body does.

How Bioexcel Can Help

At Bioexcel, we support medical device and IVD manufacturers across the full clinical and regulatory evidence lifecycle.

Our team supports MDR Clinical Evaluation, IVDR Performance Evaluation, Clinical Investigation, PMS, PMCF, PMPF, Notified Body remediation, evidence gap assessment, and technical documentation alignment.

We help manufacturers build connected, defensible, and review-ready evidence packages.

Is your MDR or IVDR evidence package ready for 2026 expectations? Partner with Bioexcel for a structured EU MDR/IVDR Clinical Evidence and Technical Documentation Gap Assessment.